Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Kamali, Xiayizha ^a   Wulasihan, Muhuyati ^a   Yang, Yu Chun ^a   Lu, Wu Hong ^a   Liu, Zhi Qiang ^a   He, Peng Yi ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Gene polymorphism; GGCX gene; Warfarin

Indexed keywords

CARBOXYLASE; GAMMA GLUTAMYL CARBOXYLASE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CHINA; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CARBON-CARBON LIGASES; DRUG DOSAGE CALCULATIONS; DRUG TOLERANCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTRACRANIAL EMBOLISM; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 84886009562     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-149     Document Type: Article

References (21)

1. Retrospective survey of hospitalized patients with atrial fibrillation in some areas of China. China Cardiovascular Association, Zhonghua Xin Xue Guan Bing Za Zhi 2003 913 916
2. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Barrios V, Escobar C, Expert Opin Pharmacother 2012 13 2649 2661 10.1517/14656566.2012.749860 23167273
3. Recent clinical trials in atrial fibrillation in hypertensive patients. Manolis AJ, Kallistratos MS, Poulimenos LE, Curr Hypertens Rep 2012 14 350 359 10.1007/s11906-012-0268-5 22576674
4. Influence of GGCX genotype on warfarin dose requirements in Chinese patients. Huang SW, Xiang DK, Huang L, Chen BL, An BQ, Li GF, Luo ZY, Thromb Res 2011 127 131 134 10.1016/j.thromres.2010.10.027 21195460
5. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M, Blood 2005 106 3673 3674 10.1182/blood-2005-04-1711 16267263 (Pubitemid 41609210)
6. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Shuen AY, Wong BY, Fu L, Selby R, Cole DE, Clin Biochem 2012 45 397 401 10.1016/j.clinbiochem.2012.01.002 22266406
7. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Yang L, Ge W, Yu F, Zhu H, Thromb Res 2010 125 159 e166 10.1016/j.thromres.2009.10.017 19942260
8. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism. Rai AJ, Udar N, Saad R, Fleisher M, Clin Chem 2009 55 823 826 10.1373/clinchem.2008.118497 19233910
9. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS, BMC Med Genet 2011 12 80 21639946
10. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2. Scott SA, Patel M, Martis S, Lubitz SA, van der Zee S, Yoo C, Edelmann L, Halperin JL, Desnick RJ, GGCX and CALU. Pharmacogenomics. 2012 13 297 307 10.2217/pgs.11.156
11. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis. Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, Zhang Y, Xu Q, Wang H, Li Y, Lu C, Chen W, Zeng C, Yin T, Int J Cardiol 2013 doi:pii: S0167-5273(13)01362-4. doi:10.1016/j.ijcard.2013.07.151
12. Association of Sequence Variations in Vitamin K Epoxide Reductase and γ-Glutamyl Carboxylase Genes with Biochemical Measures of Vitamin K Status. Crosier MD, Peter I, Booth SL, Bennett G, Dawson-Hughes B, Ordovas JM, J Nutr Sci Vitaminol (Tokyo) 2009 55 112 119 10.3177/jnsv.55.112 19436136
13. The vitamin K cycle. Stafford DW, J Thromb Haemost 2005 3 1873 1878 10.1111/j.1538-7836.2005.01419.x 16102054 (Pubitemid 41716574)
14. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T, Thromb Res 2007 120 181 186 10.1016/j.thromres.2006.09.007 17049586 (Pubitemid 46754413)
15. New adjuvants to enhance anticoagulant activity of warfarin. Stromich JJ, Weber AK, Mirzaei YR, Caldwell MD, Lewis DE, Bioorg Med Chem Lett 2010 20 1928 1932 10.1016/j.bmcl.2010.01.123 20167480
16. Functional polymorphism in gamma-glutamylcarboxylase is a risk factor for severe neonatal hemorrhage. Vanakker OM, De Coen K, Costrop L, Coucke PJ, Vanhaesebrouck P, De Paepe A, J Pediatr 2011 159 347 349 10.1016/j.jpeds.2011. 04.044 21704322
17. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P, Pharmacogenomics J 2005 5 262 270 10.1038/sj.tpj.6500313 15883587 (Pubitemid 41131718)
18. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. Rieder MJ, Reiner AP, Rettie AE, J Thromb Haemost 2007 5 2227 2234 10.1111/j.1538-7836.2007.02744.x 17764537 (Pubitemid 47617875)
19. Familial deficiency of vitamin K-dependent clotting factors. Weston BW, Monahan PE, Haemophilia 2008 14 1209 1213 10.1111/j.1365-2516.2008.01853.x 19141161
20. New genetic variant that might improve warfarin dose prediction in African Americans. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE, Br J Clin Pharmacol 2010 70 393 399 10.1111/j.1365-2125.2010.03709.x 20716240
21. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. D'Andrea G, D'Ambrosio R, Margaglione M, Blood Rev 2008 22 127 140 doi:10.1016/j.blre.2007.11.004 10.1016/j.blre.2007.11.004 18234403